In the News

‍

Tom Brady teams with digital health firm eMed to expand GLP-1 weight loss medication access

Watch the full segment with eMed's Linda Yaccarino and Tom Brady from FOX Business's Claman Countdown with Liz Claman.

Crux and eMed Partner to Expand Affordable Access to GLP‑1 Therapies for Working Americans

Tom Brady & Linda Yaccarino on Bloomberg News

Former NFL Quarterback Tom Brady & eMed CEO Linda Yaccarino discuss investment in health startup eMed, soaring GLP-1 weight-loss drug costs, and how to evaluate business opportunities as a well-known former athlete. They speak with Katie Greifeld and Romaine Bostick at the Milken Institute Global Conference in Beverly Hills, California.

eMed expands access to GLP-1 care for healthcare professionals

Employee Benefit News is spotlighting what we're building and why it matters right now. The piece features our work with Tom Brady on expanding access to clinically managed GLP-1 care for healthcare professionals

eMed reaches $2 billion valuation

The digital health company raised $200 million in series A funding to advance its AI-powered platform for GLP-1 weight loss medications.

eMed is partnering with CVS

As covered in Axios, eMed is partnering with CVS to provide employers with a structured, cost-controlled pathway to offer GLP-1 medications, combining responsible access with comprehensive medical support.
Smiling woman with long dark hair wearing a sleeveless purple top against a dark background.

eMed Population Health Appoints Dr. Dyan Hes as Chief Medical Officer

Click here to read the full press release
AON and eMed combined logo with AON in red and eMed in white on black background.

Aon Announces Strategic Investment in eMed

Red AON logo text on a black background.

Aon and eMed: First Workforce-Focused Analysis on GLP-1s to Transform Workforce Health and Bend the Cost Curve

Tom Brady named Chief Wellness Officer of eMed

Sports icon partners with leading population health program to advance preventive employee healthcare
Bottle of Wegovy 1.5 mg semaglutide tablets with two white pills, one embossed with 'novo'

eMed provides access to FDA-Approved Wegovy® pill through its trusted, clinically guided model of care.

Click to read the full press release

GLP-1/GIP Articles

GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment

Use of GLP-1 drugs for weight loss skyrocketed 700% - from 21,000 non-diabetic users in 2019 to 174,000 in 2023.
Read more

Weight-loss drug coverage rises among largest US employers, Mercer survey finds

About 44% of U.S. employers with 500 or more employees cover drugs for weight loss in 2024, up from 41% in 2023.
‍
Read more
Booming market has raised safety concerns, with many users left in debt or even in hospital.
Read more

Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes management

This study presents a budget impact analysis, evaluating the cost implications of adopting GLP-1 medications in the management of type 2 diabetes patients.
Read more

FDA approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death

GLP-1s reduce kidney disease risk in diabetes
Read more

Novo’s Semaglutide Linked to Reduced Alzheimer’s Risk in Real-World Study

Researchers link Novo Nordisk’s semaglutide to a 40–70% lower Alzheimer’s risk in a study of 1M patients.
Read more

Clinical Information

Changes in Adult Obesity Trends in the US

The findings suggest that BMI and obesity prevalence in the US decreased in 2023 for the first time in more than a decade. The most notable decrease was in the South, which had the highest observed per capita GLP-1RA dispensing rate.
Read more

Government plans to tackle obesity in England

Over one in four (26%) adults and 23.4% of children aged 10-11 years in England are living with obesity, placing huge pressure on the health and care system.
Read more

New Study Links Obesity to Elevated Hypertension Risk Among Young Middle Eastern Women

Obesity is a widespread public health challenge in the Middle East. The findings highlight the urgent need for targeted interventions to reduce the cardiovascular risk burden
Read more

The relationship between HbA1c reduction and healthcare costs among patients with type 2 diabetes, July 2020

Results suggest that there are economic benefits associated with HbA1c reduction
Read more

Reset your expectation with Mounjaro



GLP-1 Reduces AIC by an average of 2%


‍
Read more

The Cost of Obesity in Seven Graphs and the Impact of Lifestyle Medicine

Healthcare costs 100% more for obese vs. non-obese employees. A study in the Journal of Managed Care + Specialty Pharmacy found increases in all major categories of medical care for adults with obesity, particularly inpatient services and prescription drug expenditures.
Read more

Association of body mass index with health care expenditures in the United States by age and sex

Higher health care costs are associated with excess body weight across a broad range of ages and BMI levels, and are especially high for people with severe obesity.
Read more

Adult Obesity Facts

Obesity is a serious, common, and costly chronic disease. More than 2 in 5 U.S. adults have obesity. See the adult obesity facts, CDC
Read more

It’s Shockingly Easy to Buy Off-Brand Ozempic Online, Even if You Don’t Need It

Weight-loss drugs like Ozempic are in shortage, and telehealth startups are selling “compounded” versions. A WIRED investigation looks at how easy it is to order these meds online.
Read more

Amid Regulatory Gaps, Telehealth Prescribers Flourish

It’s easier than ever to get prescription drugs online. Should regulators be paying more attention?
Read more

Novo Nordisk aware of reports 10 people taking compounded weight-loss drug copies died

Increased hospitalizations resulting from unmanaged events, exposure to unregulated ingredients, and improper medication administration.
Read more

For press inquiries email - press@emed.com